AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and VEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio -

CAMBRIDGE, Mass. Jan. 04, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, today announced it has acquired from Kirin Brewery Co., Ltd. an exclusive license to develop and commercialize Kirin’s highly potent and selective, once-a-day, oral VEGF receptor inhibitor, KRN951, in all territories outside of Asia. Financial terms of the agreement were not disclosed.

KRN951 is currently completing a 30-patient Phase I clinical trial in patients with advanced solid tumors in which the maximum tolerated dose of KRN951 has been established. Results recently presented at the EORTC-NCI-AACR meeting in Prague by lead investigator Dr. Ferry Eskens of the Department of Medical Oncology, Erasmus Medical Center in Rotterdam, found that of seven patients with refractory renal cell carcinoma enrolled to date, all have achieved either a partial response or stable disease as defined by the trial protocol, with one patient exhibiting a response lasting more than 2.5 years. Treatment with KRN951 in the trial was well-tolerated. The most common side effect seen in the trial was hypertension — an expected mechanism-based toxicity. Blood pressure was readily controlled by standard antihypertensive agents in all but one of the patients who developed hypertension during the trial.

psa-rising.com homepage has added a button, which looks like this .

On some pages you’ll see a tiny button on the navigation bar at the top of the page.

RSS stands for Really Simple Syndication. It’s a way of spreading a websites’s new content as soon as updated. You can receive this content in several ways — as headlines via your browser’s Bookmarks Toolbar Folder; as headlines and intros via a feed reader service like My Yahoo’s, Google’s and AOL’s (right now we can’t get AOL’s to work); and even through your cell phone.

January 5, 2007. Seventy-four percent of men treated with a combination of radiation seed implants and external beam radiation therapy for prostate cancer are cured of their disease 15 years following their treatment, according to a study released today in the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.

“This study is exciting because it shows that the combination of brachytherapy and external beam therapy are successful long-term at curing men of their prostate cancer,” said lead autor John E. Sylvester, M.D. Full story ….

A study of almost 40 thousand Israeli men has found that men who have fathered sons are at lower risk for prostate cancer than men who have daughters but no sons. The researchers suggest that this shows the Y chromosome is involved in prostate cancer.

A new study says that cancer patients spend $2.3 billion worth of time in waiting rooms, doctors’ offices, hospitals and transportation in the first year after cancer is diagnosed.

Patients with cancers that can be detected early spend least wait time both in the year after diagnosis and in the last year of life.

Medicare patients with gastric and ovarian cancers lost the most time in the initial year, valued around $5,300 and $5,600 per person, compared with costs associated with skin, prostate and breast cancers of around $300, $800 and $1000 each.

Us TOO to host FREE Tele-Conference Call on Intimacy & Prostate Cancer

The Us TOO International Companions & Family Advisory panel will
host the FREE, nationwide teleconference program, “Intimacy and
Prostate Cancer.” This FREE program will take place on February 13th;
9pm ET, 8pm CT, 7pm MT, 6pm PT.

RSVP: This conference will fill quickly, so RSVP today by
contacting Dan Reed at [email protected], or call (800) 808-7966.
You may remain anonymous when you RSVP if you choose, but please
RSVP so we can reserve ample space for all who wish to
participate.